Guggenheim Capital LLC Has $886,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

Guggenheim Capital LLC decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 31.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,065 shares of the company's stock after selling 8,645 shares during the quarter. Guggenheim Capital LLC's holdings in Twist Bioscience were worth $886,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience during the third quarter valued at about $34,000. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the last quarter. US Bancorp DE grew its holdings in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter worth $95,000. Finally, KBC Group NV boosted its holdings in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after buying an additional 1,226 shares during the period.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the sale, the chief executive officer now directly owns 667,318 shares of the company's stock, valued at approximately $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the transaction, the senior vice president now owns 132,014 shares of the company's stock, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,432 shares of company stock worth $1,038,170. Corporate insiders own 3.01% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on TWST shares. Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a research report on Friday, March 28th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $52.80.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $0.49 during trading on Monday, hitting $39.62. 507,458 shares of the company's stock traded hands, compared to its average volume of 1,063,454. The company has a market cap of $2.36 billion, a PE ratio of -11.68 and a beta of 2.34. The firm's fifty day moving average price is $39.67 and its 200 day moving average price is $44.29. Twist Bioscience Co. has a twelve month low of $30.32 and a twelve month high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.75) earnings per share. Analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.